ORAL DELIVERY OF RECOMBINANT PROTEINS
Acorn’s lead technology, T-Fusion™ is a platform that
enables an expanding class of therapeutic agents
now on the market – recombinant
therapeutic proteins - to be given orally rather
than by injection as all are now administered. T-Fusion™ uses
transferrin, a transport protein that is resistant to gastrointestinal
digestion, to orally deliver therapeutically effective doses of proteins
to the body. Our leading candidate, ACN-8337,
is an oral formulation of G-CSF, utilizing the T-Fusion™ technology.
T-Fusion™ is applicable to the oral delivery of a wide range
of recombinant therapeutic proteins, such as erythropoietin, growth
factors, blood clotting factors, growth hormones, reproductive hormones,
and replacement enzymes. The worldwide market for therapeutic recombinant
proteins was over $40 Billion in 2007.
WHY ORAL DELIVERY OF RECOMBINANT PROTEINS?
Recombinant protein and peptide pharmaceuticals have become mainstream
in the pharmaceutical industry with every major drug company developing
and marketing such products. Recombinant proteins are man-made proteins
that replicate existing proteins that serve various functions in the
body. Typically, these drugs help patients - whose bodies are compromised
due to illness, disease or treatment regimen - to produce desired proteins.
Patients now take these drugs by injection, as no other alternatives
are commercially available.
Despite a demonstrated need for protein and peptide drugs, doctors
and patients can be reluctant to prescribe and use such medications
because of the need to have frequent repeat injections to acquire and
maintain a therapeutically useful drug dosage. It is thought that by
enabling protein and peptide therapeutics to be administered orally,
doctors can improve drug bioavailability, increase the ease of administration
of these drugs, and generate wider patient use and acceptance. Substantial
cost savings would be afforded to the health care industry by eliminating
or reducing the number of patient visits and related costs associated